Sanofi expects $120 million hit as dengue vaccine hits major snag

PARIS (Reuters) - Use of Sanofi's dengue vaccine, the world's first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen disease in people who have not previously been exposed to the infection.